Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS

  • Alexandra S. Kocsik
  • David E. Klein
  • Maryana Liedke
  • Ulrike W. Kaunzner
  • Nancy M. Nealon
  • Susan A. Gauthier
  • Timothy Vartanian
  • Jai S. Perumal
Short Commentary

Abstract

Objective

To investigate a single-course treatment with alemtuzumab in patients with relapsing–remitting multiple sclerosis.

Methods

We performed a retrospective chart review of all patients diagnosed with RRMS who were treated with alemtuzumab at our MS center and who had at least 12 month follow-up since the first dose. Data on radiological and clinical relapse were collected for the 2 years prior to patients’ first dose of alemtuzumab and were tracked until the time of analysis.

Results

In the 2 years prior to first dose of alemtuzumab, 82.8% of the 29 patients had a new lesion on MRI and/or a clinical relapse, with an ARR of 0.67. In the mean 24.7 month follow-up after the first dose of alemtuzumab, 17.2% of patients displayed new disease activity and the ARR was 0.08. 4 out of 5 patients who relapsed did so within 12 month post-first infusion and received a second dose. Of the 24 patients who did not relapse, 8 received a second dose at 1 year and 16 did not. 5 out of all 29 patients developed thyroid disorder.

Conclusions

Given that 96% of patients who did not relapse in the first 12 months following the initial dose of alemtuzumab remained relapse-free regardless of receiving a second course of drug, our data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab. With further study, these data could support modification of the current therapy regimen.

Keywords

Multiple sclerosis Alemtuzumab Disease-modifying therapy Relapse 

Notes

Compliance with ethical standards

Ethical standards

This study has been approved by the local institutional review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Genzyme (2016) Lemtrada [prescribing information]. Genzyme Corporation, CambridgeGoogle Scholar
  2. 2.
    Cohen JA, Coles AJ, Arnold DL et al (2012) CARE MS I Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828.  https://doi.org/10.1016/S0140-6736(12)61769-3 CrossRefPubMedGoogle Scholar
  3. 3.
    Coles AJ, Twyman CL, Arnold DL et al (2012) CARE MS II Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839.  https://doi.org/10.1016/S0140-6736(12)61768-1 CrossRefPubMedGoogle Scholar
  4. 4.
    Havrdova E, Arnold DL, Cohen JA et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89:1107–1116.  https://doi.org/10.1212/WNL.0000000000004313 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Coles AJ, Cohen JA, Fox E et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89:1117–1126.  https://doi.org/10.1212/WNL.0000000000004354 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Al-Sawaf O, Fischer K, Herling CD et al (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol 98:254–262.  https://doi.org/10.1111/ejh.12825 CrossRefPubMedGoogle Scholar
  7. 7.
    Osterborg A, Foa R, Bezares RF et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980–1988.  https://doi.org/10.1038/leu.2009.146 CrossRefPubMedGoogle Scholar
  8. 8.
    Sylvan ES, Lundin J, Ipek M et al (2014) Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol 83:1725–1733.  https://doi.org/10.1007/s00277-014-2105-1 CrossRefGoogle Scholar
  9. 9.
    Morgan RD, O’Callaghan JM, Knight SR et al (2012) Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 93:1179–1188.  https://doi.org/10.1097/TP.0b013e318257ad41 CrossRefPubMedGoogle Scholar
  10. 10.
    Van der Zwan M, Baan CC, Van Gelder T et al (2018) Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet 57:191–207.  https://doi.org/10.1007/s40262-017-0573-x CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of NeurologyNew York-Presbyterian/Weill Cornell MedicineNew YorkUSA
  2. 2.Touro College of Osteopathic MedicineMiddletownUSA

Personalised recommendations